Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck R&D: A Jam-Packed Pipeline, But Much Of It Is Wait-And-See

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With Schering-Plough's research now tucked snugly in with Merck's, the combined company met with analysts and investors for its widely anticipated R&D overview May 11. Even as management laid out a deep mid- to late-stage pipeline especially rich in cardiovascular products, executives provided little in the way of scientific news

You may also be interested in...



Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs

As Merck heads into a “patent cliff” year, highlights of its analyst meeting included updates on key Phase III drugs, growth in emerging markets, and unveiling of new programs in Alzheimer’s disease and diabetes.

Merck Likes Biosimilars, But Not ESAs

Merck is dropping development of one of its first biosimilar drug candidates, a pegylated version of Amgen's erythropoiesis stimulating agent Aranesp (darbepoetin alfa), due to cardiovascular risks associated with the drugs and potential regulatory requirements

Merck Likes Biosimilars, But Not ESAs

Merck is dropping development of one of its first biosimilar drug candidates, a pegylated version of Amgen's erythropoiesis stimulating agent Aranesp (darbepoetin alfa), due to cardiovascular risks associated with the drugs and potential regulatory requirements

Related Content

Topics

UsernamePublicRestriction

Register

PS004455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel